Innovation Fund Denmark
Innobooster
“In SPT VILECON, every day offers innovation and new solutions. With Innvite, we ensure a sharp course for the future.”
Bjarne Andersen
CEO, SPT VILEVON A/S
Innovation Fund Denmark
“In SPT VILECON, every day offers innovation and new solutions. With Innvite, we ensure a sharp course for the future.”
Bjarne Andersen
CEO, SPT VILEVON A/S
SPT VILECON A/S specializes in the development of MedTech products. Now the next big goal is to develop a device for vacuum-assisted fine needle biopsy, where the patient experience the fewest possible inconveniences, while the doctor achieves greater safety and sufficient sample material to ensure correct diagnosis.
One of the important applications for fine needle biopsy is breast cancer, which is the most frequent form of cancer among women in Denmark. It is also a global challenge. In the United States alone, more than 1 million breast biopsies are performed each year.
For certain types of biopsy, a coarse needle is used to ensure sufficient sample material. The ambition is to take shares from the market for coarse needle biopsy over to fine needle biopsy. When it is possible to provide a better alternative to core needle biopsy, the patient will be free from anesthesia and will simply notice the procedure in line with a simple blood test.
The project is supported by the Innovation Fund’s Innobooster programme.
The target audience for the final product is radiologists on a global scale who perform biopsies on patients. The first market focus will be fine needle aspiration in Europe and the U.S, while the greatest growth in the long term is expected in Asia.